Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC).

被引：0
|
作者：
Baselga, J
Gianni, L
Llombart, A
Manikhas, G
Kubista, E
Steger, G
Lee, H
Ronczka, A
Xu, L
Clark, E
Vall d'Hebron, GSV
机构：
[1] Vall Hebron, Barcelona, Spain
[2] Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy
[3] Inst Valenciano Oncol, Valencia, Spain
[4] Municipal Oncol Outpatient Clin, St Petersburg, Russia
[5] Med Univ Vienna, Vienna, Austria
[6] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [1] Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data.
    Cussac, AL
    Baselga, J
    Manikhas, G
    Kubista, E
    Steger, G
    Galbraith, SM
    Sullivan, MA
    Zerba, K
    Lee, H
    Gianni, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 25S - 25S
  • [2] Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
    Baselga, Jose
    Zambetti, Milvia
    Llombart-Cussac, Antoni
    Manikhas, Georgy
    Kubista, Ernst
    Steger, Guenther G.
    Makhson, Anatoly
    Tjulandin, Sergei
    Ludwig, Heinz
    Verrill, Mark
    Ciruelos, Eva
    Egyhazi, Suzanne
    Xu, Li-An
    Zerba, Kim E.
    Lee, Hyerim
    Clark, Edwin
    Galbraith, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 526 - 534
  • [3] Ixabepilone: A novel microtubule-stabilizing agent for the treatment of metastatic breast cancer
    Goodin, Susan
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (21) : 2017 - 2026
  • [4] Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
    Egerton, Nancy
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1005 - 1012
  • [5] Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
    Nancy Egerton
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1005 - 1012
  • [6] Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study
    Clavarezza, Matteo
    Bordonaro, Roberto
    Daniele, Bruno
    Ferrandina, Gabriella
    Barni, Sandro
    Turazza, monica
    Coati, Francesca
    De Matteis, Andrea
    De Placido, Sabino
    Cognetti, Francesco
    Olmeo, Nina Antonina
    Carrozza, Francesco
    Bruzzi, Paolo
    Del Mastro, Lucia
    ONCOLOGIST, 2013, 18 (08): : 924 - 925
  • [7] Analysis of ixabepilone exposure-response for neutropenia in patients with metastatic breast cancer
    Roy, A.
    Zhu, H.
    Cohen, M.
    Zhang, L.
    Pfister, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Clinical activity of the novel epothilone B analog, ixabepilone, in triple negative breast cancer (BC) patients
    Pivot, X.
    Llombart-Cussac, A.
    Martin, M.
    Verrill, M.
    Peck, R.
    Conte, P. F.
    EJC SUPPLEMENTS, 2008, 6 (07): : 134 - 135
  • [9] A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer
    Roche, Henri
    De Benedictis, Elena
    Cottura, Ewa
    Govi, Silvia
    Dalenc, Florence
    Locatelli, Alberta
    Deslandres, Marion
    Zambetti, Milvia
    Gladieff, Laurence
    Messina, Marianne
    Gianni, Luca
    CLINICAL BREAST CANCER, 2012, 12 (03) : 167 - 174
  • [10] Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes:: subgroup analysis of patients receiving ixabepilone in the first-line setting
    Jassem, J.
    Thomas, E.
    Gomez, H.
    Li, R. K.
    Chung, H. C.
    Fein, L. E.
    Chan, V. F.
    Peck, R. A.
    Mukhopadhyay, P.
    Roche, H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 213 - 214
12345